Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo Efficacy

Sterile alpha and TIR Motif Containing 1 (SARM1) is a nicotinamide adenine dinucleotide (NAD<sup>+</sup>) hydrolase that plays a central role in programmed axonal degeneration. Axonal degeneration has been linked to neurodegenerative and neurological disorders such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and peripheral neuropathies. Therefore, developing potent and selective SARM1 inhibitors could be an effective strategy to treat these disorders. We present herein the structure-guided discovery of two novel SARM1 inhibitors, <b>7</b> and <b>35</b>. Compounds <b>7</b> and <b>35</b> are potent inhibitors across assays and possess favorable ADMET properties. When tested in vivo, compound <b>7</b> showed efficacy after oral dosing in a mouse model of peripheral nerve injury by decreasing plasma neurofilament light (NfL) levels at 50 mg/kg compared with vehicle-treated control mice, holding promise for the treatment of neurodegenerative and neurological disorders.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-03-18
DOI
https://doi.org/10.1021/acs.jmedchem.4c03127
Citations
8
Primary Topic
Endoplasmic Reticulum Stress and Disease
Type
article
Field-Weighted Citation Impact
9.21
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo Efficacy

Ahmed Haider, M Giroud, Didier Rombach, Philipp Schmid et al.
8 citations
Journal of Medicinal Chemistry
Endoplasmic Reticulum Stress and Disease
9.21
article

Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo Efficacy

Ahmed Haider, M Giroud, Didier Rombach, Philipp Schmid, Sandra Steiner, Matthias Wittwer, Wolfgang Haap, Sissy Kalayil, Marta Mendel, Emmanuel Pinard, Uwe Grether, Catherina Gasser, Claudia Bonardi, Claudio Zambaldo, Martin Ritter, Bernd Kuhn, Alessandro Brigo, Inken Plitzko, Paul Westwood, James Keaney, Andreas Topp, Manuel Hilbert, Wiebke Saal, Dominique Burger, Anisha Mani, Jörg Benz, Paola Caramenti, Nina Aregger, Nora Séchet, Matthew Bilyard, Alexia Malnight-Alvarez
article en
8 citations

Abstract

Sterile alpha and TIR Motif Containing 1 (SARM1) is a nicotinamide adenine dinucleotide (NAD<sup>+</sup>) hydrolase that plays a central role in programmed axonal degeneration. Axonal degeneration has been linked to neurodegenerative and neurological disorders such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and peripheral neuropathies. Therefore, developing potent and selective SARM1 inhibitors could be an effective strategy to treat these disorders. We present herein the structure-guided discovery of two novel SARM1 inhibitors, <b>7</b> and <b>35</b>. Compounds <b>7</b> and <b>35</b> are potent inhibitors across assays and possess favorable ADMET properties. When tested in vivo, compound <b>7</b> showed efficacy after oral dosing in a mouse model of peripheral nerve injury by decreasing plasma neurofilament light (NfL) levels at 50 mg/kg compared with vehicle-treated control mice, holding promise for the treatment of neurodegenerative and neurological disorders.

Journal of Medicinal ChemistryVol. 68(6)
Roche (Switzerland) (CH)
Openalex Percentile: Top 2%
Endoplasmic Reticulum Stress and Disease
9.21
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.